the ceo of bio tech firm joins me next to talk about that and the partnership with eli lilly and the new round of funding. >>> disney world revealing the plans to reopen. we have a look at how and when they plan to keep people safe. >>> you can watch or listen to us live on the go on the cnbc app. "the exchange" is back in a couple this is decision tech. find a stock based on your interests or what's trending. get real-time insights in your customized view of the market. it's smarter trading technology for smarter trading decisions. fidelity. truly transformative sleep. so, no more tossing and turning. because only tempur-pedic adapts and responds to your body... ...so you get deep, uninterrupted sleep. during the tempur-pedic summer of sleep, all tempur-pedic mattresses are on sale! >>> welcome back now to the very latest in the coronavirus pandemic over to sue herera for our headlines. s sue? >> new york governor cuomo meeting with president trump at the white house. the meeting closed to reporters but yesterday cuomo said he would discuss the reopening plans and that state's econo

i would like to also invite up the chairman and ceo of eli lilly and company. a very big and a very great company. another young guy. >> thank you, mr. president. an honor to be a part of this announcement to improve the lives of so many patients who live with diabetes. for several years, we have worked hard to improve insulin affordability. this has been a missing piece that has been filled in from our ruce's, viceke b president pence, president trump. thank you for your leadership to make this happen. this is the kind of collaboration that solves problems for people with issues like diabetes. into, if you take lily lynn, you will not pay more than $35 except for in the party program. we are pleased to add this missing part to the equation so that starting next year, seniors will benefit from the same savings level. just a little bit more than a dollar a day for insulin. that same spirit of collaboration is being applied to covid-19. everyone is aware or thousands of scientists working in our industry along with nih and speed therapies and tong from covid-19 e

infectious diseases just say now it is testing gilead science remdesivir in combination with an eli lilly drug in part of a next phase of a clinical trial and the study will enroll about 1,000 people at more than 100 sites in the u.s. and abroad, and remdesivir of course is one of the treatments being eyed as the cure for covid-19. right now, we do have gilead science is down about half a percent after seeing quite a run -up over the past couple of weeks and eli lilly is moving higher by half a percent. granted we are only eight days into may, but spirit airlines report they are seeing an up-tick in demand for the month, compared to april , when we know the bottom fell out of the entire airline industry after the coronavirus virtually shutdown the airlines the comeback is welcome but it is slow, folks. jet blue has slashed its daily number of flights from 1,000 to 100 and today though it's getting a nice move up 9.6%, spirit pulling back today, 1.5%. we have a good news/bad news final hour of trade for disney. tickets for shanghai disneyland, may openings sold out in just minute, even as

. >> president trump: like to invite up chairman and ceo of eli lilly and company.big in a very great company. another young guy. >> a pleasure to be here. really an honor to be part of this announcement to improve the lives of so many patients who live with diabetes in our program. for several years, we've worked hard to improve insulin affordability. this has been a missing piece that has now been filled in by the great collaboration from our companies. your administration. in vice president pence, president trump, thank you for your leadership to make this happen. this is the kind of leadership that solves real problem with serious issues like diabetes. today if you take the lily insulin, you will not pay more than $35 except for in the part d program. we are pleased to add this missing part of the equation so starting next year, seniors will benefit from the same savings level a little bit more than a dollar a day for insulin. that same spirit of collaboration is being applied to the collaboration around covid-19. and i think everyone is aware that there is thou

i would also like to invite up, david rings, chairman, ceo of eli lilly and company.ery big and great company, please. another young guy. >> thank you, mr. president. >> thank you, david. >> pleasure to be here. really an who are no be a part of this announcement. improve lives of so many patients that live with diabetes in our part d program. for several years lily worked hard to improve insulin affordability this is piece filling in plan like companies like bruce's are here, seema verma, your administration, vice president pence, president trump, thank you for your leadership to make this happen. this is the kind of collaboration that solves real problems for people with serious issues like diabetes. today, if you take lily insulin, you will not pay more than $35, except in the part d program. we're pleased to add the missing part to that equation, starting next year, seniors will benefit from that same savings level, just a little bit more than a dollar a day for insulin. that same spirit of collaboration is being applied to collaboration around covid-19 and i thin

lilly?e up with eli >> thank you very much. this is tremendous. big recognition by a global pharmaceutical company pew -- company. it allows us to accelerate our covid-19 program. with their operational capacity, the agreement has the potential to reach a wider range of countries and regions. haslinda: in terms of the antibody you are working on, how much progress has been made, and are you set for clinical trials, for instance? ofng: since the beginning the covid-19 outbreak, in january, we have launched the research and development program for the antibody against covid-19. for about three months, we have study,ed the pre-clinic the process developments, and manufacturing of clinical materials. aimther with eli lilly, we for the second quarter of this year for testing. treatment will be available for some patients. how does neutralizing an antibody work? it is very different from a vaccine. sheng: yes. collaborate --m basically we collaborated in late january. antibodyal occurring from a patient who recovered from covid-19. those antibodies are

indianapolis-based eli lilly is partnering to develop a neutralizing antibody to treat covid-19.f that antibody will be done at lilly's indianapolis plants. and the f.d.a. just gave approval to an antibody test that will start shipping from roche diagnostics's indianapolis location. it can help determine if plasma from the blood of a donor can be used to treat other patients or keep others from getting the coronavirus. feeling a little chili? so are many in the nation from the midwest to the northeast. this was the snowy scene in bethlehemn pennsylvania. the blast of wintry weather could shatter more than 40 records from louisiana to massachusetts. well, straight ahead on the "cbs weekend news", celebrating the 75th anniversary of victory in europe amid the fight against the pandemic. the virus has devastated venice, italy. why volunteers there are rowing to the rescue. plus... ♪ ♪ >> reporter: musicians in new orleans get creative to survive quarantine. f i can fight moderao severe rheumatoid arthritis. proof i can fight psoriatic arthritis... ...with humira. proof of less joint

we have the likes of cardinal health 5.2%, and some of the other health care stocks like gilead, eli lilly up more than 2.5% apiece. under armour continues the guidance story, not giving any indication of what it is expecting, but says the current quarter will be the most impacted by the coronavirus. shares are down about 11%. the yen we getting today. stronger dollar once again. food is unchanged -- crude is unchanged, $24 a barrel. guy: interesting to see that spread between brent and wti widening out. let's figure out what is happening in the markets and what is going on in terms of portfolio construction. riserto gallo from algeb investments is joining us on the line. we are trying to figure out how we reopen an economy in the united states. we've got the u.k. starting to think about reopening its economy, or at least the english part of the u.k. economy. france, germany, italy, spain, everyone is trying to figure out how to do this, but they are all trying to do it at different rates. i am just wondering, from a portfolio point of view, the global asset allocation point of view, you a

. >> eli lilly, he made the quarter so -- baxter, put that on, because i'm going to be with steph. d dexcom, just did a convert at 0.25 it had a very big run. dwl glaxo is finally moving and if you want to know who is on the far turn is the glaxo/sanofi vaccine, which is very good. abbott, there's a story today about the new york -- the nyu hospital that says that their tests are unreliable i directly dispute that. they are doing things wrong, they're not doing the tests right. they're doing the time of transport is too long and they're doing the tests wrong. they're using viral transport medium -- forget the complaint it's wrong abbvie, can't wait to speak to them that combination is great. another steph name sensy, incredibly cheap. you cannot beat them in terms of medicare, medicaid for managed care united health. my hat is off to them. can they be better gilead, too much promote, not a lot of bad money coming down and it will be fine. >> hey, pete -- >> regeneron, by the way, is the one that have will the antibody. >> i don't know if cramer is looking to pick a fight with you,

all are going to be starting in the next few months, including regeneron, eli lilly and amgen we are almost and we will see the more the merrier. the reason you want more neutralizing antibodies from different pockets so you have redundancy and see which one pans out and certainly potentially could be sinner in guestic. using neutralizing antibody has the effect to say if the virus mutates some of the antibody may not work after the mutation, so if you have a different angles from different antibodies attack the same virus, you may have the redundancy you need and also you have the antibody potentially generate body resistance to it after prolonged use, so you want to have multiple parties all coming here with different of neutralizing antibody that will help us tremendously >> doctor, it's david faber. there are those who say and focused on this and say it isn't that hard to generate an antibody, it's what comes next in terms of a timeline where you can get to a place that you can manufacture it significant scale. regeneron saying they have that down to what could be six months, but

eli lilly, am gen agen are in tc as well.they create or isolate antibodies people who recovered from covid-19 or in some cases original sars and antibodies are part of our immune response to neutralize the virus remdesivir is an anti-viral that interferes with the virus' ability to replicate multiple different approaches going after the virus and ones if successful could be combined to have an even better therapeutic effect >> fauci suggested that. meg, thank you very much and we look forward to some of your interviews from our healthy returns conference >>> how states are faring when they lift coronavirus restrictions with government officials struggling to find that balance between human safety and economic revival. an example since iowa began loosening restrictions may 1st it's seen a 73% increase in cases an average of 475 cases per day, but testing has increased in that state by 82%, big part of the story there. of all of those tested in iowa, 16% have tested positive iowa was one of the few states never to issue stay-at